2-(3-pyridylthio)pyrimidine

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(3-pyridylthio)pyrimidine
• 英文别名: 2-Pyridin-3-ylsulfanylpyrimidine；2-pyridin-3-ylsulfanylpyrimidine
• 化学式: C₉H₇N₃S
• 分子量: 189.241
• InChiKey: AFAXJJPAGZEUGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-吡啶溴化镁 、 2-thiocyanatopyrimidine 以 四氢呋喃 为溶剂， 反应 1.0h， 以76%的产率得到2-(3-pyridylthio)pyrimidine
  参考文献：
  名称：

  Nagasaki, Izuru; Matsumoto, Miyuki; Yamashita, Masanori, Heterocycles, 1999, vol. 51, # 5, p. 1015 - 1024

  摘要：

  DOI：

文献信息

• RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES
  申请人：Singapore Health Services Pte Ltd

  公开号：EP2972323A2

  公开（公告）日：2016-01-20
• RATIONAL COMBINATION THERAPY FOR THE TREATMENT OF CANCER
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：EP3359196B1

  公开（公告）日：2022-03-16
• METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS
  申请人：University of Houston System

  公开号：US20210401987A1

  公开（公告）日：2021-12-30

  The present disclosure addresses inflammatory lung diseases, such as COPD, and fibrotic lung diseases such as idiopathic pulmonary fibrosis, from the standpoint of inhibiting or ablating pathogenic epithelial stem cells found in the pulmonary tract.
• US9797883B2
  申请人：——

  公开号：US9797883B2

  公开（公告）日：2017-10-24
• [EN] RE-TRAFFICKING OF HERG REVERSES LONG QT SYNDROME 2 PHENOTYPE IN HUMAN IPS-DERIVED CARDIOMYOCYTES<br/>[FR] RE-TRAFIC DU PHÉNOTYPE DU SYNDROME 2 DU QT LONG INVERSE DE HERG DANS DES CARDIOMYOCYTES DÉRIVÉS DE CELLULES PLURIPOTENTES INDUITES (IPS) HUMAINES
  申请人：SINGAPORE HEALTH SERV PTE LTD

  公开号：WO2014142760A2

  公开（公告）日：2014-09-18

  The present invention relates to generating hiPSC-derived cardiomyocytes and embryoid bodies that recapitulate the disease phenotype of Long QT Syndrome and their use in developing pharmacological treatments thereof. The present invention also includes the use of a compound which inhibits the ubiquitin-proteasome pathway for the preparation of a medicament for the prophylaxis or treatment of a disease associated with prolonged ventricular repolarization (cardiac arrhythmia) caused by one or more mutations in the amino acid sequence of the hERG potassium channel.